Track Orforglipron — Daily Oral GLP-1, No Injections Required
Orforglipron is an investigational once-daily oral GLP-1 medication from Eli Lilly that doesn't require injections — and unlike oral semaglutide, can be taken with or without food. MeAgain tracks your daily dose, side effects, and weight progress so you're ready to build the habit from day one when orforglipron reaches approval. MeAgain helps you feel like you again.
Last updated March 2026
What Features Does an Orforglipron Tracking App Offer?
Daily Dose Reminders Without the Injection Anxiety
Orforglipron is a small-molecule oral GLP-1 — no needle, no pen, no injection site management. MeAgain's daily reminder and dose log make it straightforward to build the once-daily habit that oral GLP-1 medications require, with dose timing and adherence tracked automatically so nothing falls through the cracks.
Side Effect Monitoring Across Oral GLP-1 Dose Escalation
Clinical trial data for orforglipron shows GI side effects — nausea, diarrhea, vomiting — similar to injectable GLP-1 agents, concentrated in the dose escalation phase. MeAgain's daily side effect log with severity slider lets you document exactly when symptoms peak and when they ease as your body adjusts.
Nutrition and Weight Tracking Built for Daily GLP-1 Appetite Suppression
Daily oral GLP-1 suppresses appetite consistently across the day, not in a weekly injection cycle. The Capybara home screen widget tracks protein, water, fiber, and steps in real time so you stay on nutrition targets even when reduced appetite makes eating feel less urgent than it should.
Understanding Orforglipron: The Upcoming Oral GLP-1 That Doesn't Require Injections
Orforglipron (LY3502970) is an investigational once-daily oral GLP-1 receptor agonist developed by Eli Lilly. It is a non-peptide small molecule — a fundamentally different chemical structure than semaglutide or tirzepatide — which is why it can be absorbed in pill form without the strict fasting requirements of oral semaglutide. It is NOT FDA-approved and is currently in Phase 3 clinical trials, with potential approval expected in 2026-2027.
| Orforglipron (Investigational) | Oral Semaglutide (Wegovy Pill) | Injectable Semaglutide | |
|---|---|---|---|
| Type | Small molecule (non-peptide) | Peptide with SNAC enhancer | Peptide |
| Dosing frequency | Once daily | Once daily | Once weekly |
| Food restriction | None required | 30 min before food, small sip of water | None |
| Needle required | No | No | Yes |
| FDA-approved | No — investigational | Yes | Yes |
| Developer | Eli Lilly | Novo Nordisk | Novo Nordisk |
What Phase 3 Trial Data Has Shown So Far
- Weight loss of approximately 9-10% at 36 weeks in Phase 2 trials
- GI side effects (nausea, diarrhea) are the most common adverse events — concentrated in dose escalation
- No food restriction required before taking the pill
- Once-daily oral dosing removes the need for injection equipment or training
- Phase 3 trials are ongoing — final efficacy and safety data is not yet complete
- FDA approval is not guaranteed and timeline may change
MeAgain can track orforglipron via the custom medication feature today — so when it reaches approval, your habit and your history are already built. Set your daily reminder, log doses, and document side effects through the titration period from the start.
Orforglipron is an investigational medication and is NOT FDA-approved. It is available only through clinical trials. This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, changing, or stopping any medication.
Why Choose a Daily Oral GLP-1 Tracker?
The GLP-1 Experience Without the Needle
Injection anxiety is one of the most common barriers to starting GLP-1 therapy. Orforglipron's once-daily pill format removes that barrier entirely — no pen, no injection site, no sharps disposal. MeAgain's daily dose reminder and log make the habit as simple as tracking any other supplement.
Build the Daily Habit Before Approval
Orforglipron's Phase 3 data is expected in 2026-2027. MeAgain subscribers tracking via custom medication today are already building the daily routine, documenting their baseline weight and nutrition patterns, and learning what the GLP-1 adjustment period feels like — so they're prepared when the medication reaches their pharmacy.
Daily Dosing Creates Richer Data
A daily medication generates 7x the data points of a weekly injection. MeAgain's nutrition log, weight chart, side effect timeline, and dose adherence tracker all compound that density into a picture of progress that is more granular and more actionable than any weekly injectable can produce.
What Are Oral GLP-1 Subscribers Tracking?
Join the Community
Subscribers who switched from injectable to oral GLP-1 medications consistently say the daily habit requires a different approach — smaller, consistent reminders rather than one weekly event. MeAgain's dose-time log and nutrition widget keep the daily routine visible without adding friction to an already busy morning.
Over 286,000 people are tracking their GLP-1 journey with MeAgain — including subscribers on oral GLP-1 medications and those preparing for orforglipron's expected approval. For eligible subscribers, zero markup compounded semaglutide is available in-app at $123/mo with no commitments.
What Our Users Say
Orforglipron Tracker - Your Questions Answered
Orforglipron is NOT FDA-approved and is not yet commercially available. It is an investigational once-daily oral GLP-1 developed by Eli Lilly — a non-peptide small molecule that doesn't require food restrictions. Phase 3 trials are ongoing with approval expected in 2026-2027. MeAgain is ready to support tracking when it becomes available.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.